ArticleNeurogastroenterology and motility2025
Clinical Characteristics and Outcomes of Rome IV Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea Prescribed With Ondansetron: A Real-World Study.
Article in Neurogastroenterology and motility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Irritable Bowel Syndrome Clinical Care Gaps and the Potential of Future Therapeutics Based on Peripheral Visceral Afferent Modulation.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Review
- Irritable bowel syndrome with diarrhea: time to change practice?Current opinion in gastroenterology · 2026Review
- Irritable Bowel Syndrome in Inflammatory Bowel Disease: An Evidence-Based Practical Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background5-HT3 receptor antagonists, such as ondansetron, are effective in the management of irritable bowel syndrome-diarrhea predominant (IBS-D). However, real-world data and evidence exploring the response to ondansetron in patients with functional diarrhea (FDr) are lacking. The aim of this study was to assess the clinical characteristics and response to ondansetron among patients with bowel disorders associated with chronic diarrhea in a real-world setting. METHODOLOGY: We conducted a retrospective study of consecutive patients (October 2016-February 2024) diagnosed with IBS-D or FDr in a tertiary care neurogastroenterology outpatient clinic. Demographic, clinical data, previous surgery, relevant investigations and current medications were collected. Clinical response to ondansetron was defined as (i) a reduction of at least one bowel movement/day versus baseline and (ii) firmer stool consistency (an improvement of ≥ 1 on the Bristol Stool Form Scale [BSFS] vs. baseline).
resultsNinety-two patients were included, among whom 75 (81%) and 17 (18%) had IBS-D and FDr, respectively. Urgency to defecate was significantly more frequent in patients with FDr versus IBS-D (p = 0.003). Sixty-eight of the 92 patients (73.9%) reported a clinical response to ondansetron, which was maintained at a median dosage of 8 mg/day for a median duration of 19 months with few minor side effects.
conclusionWhen used in clinical practice, 8 mg/day of ondansetron is associated with a reduction in bowel frequency and an improvement in fecal consistency in approximately two-thirds of patients with IBS-D and FDr.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.